Bloomberg Intelligence cover image

Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US

Bloomberg Intelligence

00:00

Which Pharma Stocks Benefit from Obesity Demand

Scarlett and Michael analyze why large pharma pursue obesity assets and which companies may gain from the market.

Play episode from 05:55
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app